Living Proof has entered into a global venture with Valeant Pharmaceuticals International, Inc. to develop, distribute and commercialize products for aesthetic dermatology that will be sold exclusively through Valeant’s direct-to-physician channel. The transaction is worth more than $75 million in upfront and milestone payments as well as a 60/40 profit split, according to the companies. The initial product development efforts in aesthetic dermatology will be based on Living Proof’s proprietary, cross-linking polymer film technology, Strateris, which reshapes the appearance of skin.
Funded by Polaris Partners, the technology has been in development for nearly 10 years and has been tested on more than 600 women, according to Living Proof. Inspired by the attributes of youthful skin, this breathable, flexible and imperceptible film that can be worn all day to immediately reshape the appearance of skin.